According to Haemoclub International’
In particular, Vito is confident that both models of babyLance--the Preemie (BLP) and the Newborn (BLN)--and the SurgiLance SLN100 are positioned to become highly competitive players in the Italian medical product market.
Designed expressly for infants, babyLance is an ideal device for drawing blood from the heels of infants. Likewise, the SurgiLance SLN100’s needle--with 1.0mm depth of penetration--
Italy has the third-largest medical device market in Europe, according to Espicom Business Intelligence. The Italian market for medical equipment and supplies is valued at US $8.0 billion, which is equal to US $133 per capita.
According to MediPurpose President Randy Prather, who oversees the company’s global blood collection and analytics division, the timing is ripe for Italian and other European healthcare facilities to adopt these products.
“Changes in international regulatory requirements now mandate the use of single-use fingersticks,”
Both babyLance and SurgiLance have received 510(k) clearances from the U.S. Food and Drug Administration (FDA). The FDA clearances demonstrate MediPurpose’
More information about babyLance and SurgiLance--including demonstration videos and no-cost product sample requests--is available at http://www.medipurpose.com/
# # #
Founded in 1999, MediPurpose is a leading medical device company headquartered in Singapore, with offices in the United States and Europe.
Known for its popular babyLance heel incision device, SurgiLance safety lancet and MediPlus advanced wound care products, MediPurpose has leveraged its success in the medical device industry to become a master medical product distributor that provides unique solutions for both medical product manufacturers and medical product distributors.
MediPurpose's Innovation division offers angel funding and developmental expertise for new medical device inventors and innovative medical product companies that seek entrance into new medical device markets.
For more information about MediPurpose’